Phase II Study of Concurrent Lenvatinib and Radiotherapy for Advanced HCC

Inclusion Criteria: 1. Patients had an HCC diagnosis confirmed either histologically or clinically according to the Chinese Society of Clinical Oncology guidelines for primary liver cancer 2019 version； 2. Aged ≥18 years and \<80 years； 3. ECOG 0-1; 4. Live-GTV volume \> 700ml; 5. BCLC stage C, HCC with portal vein or hepatic vein tumor thrombosis or lymph node involved (LN involved can be included one treatment planning); 6. Estimated life expectancy should be more than 3 months; 7. Patients with lung and / or bone metastases can be enrolled if those metastases couldn't effect the patients' life and quality of life within 3 months; 8. Child-Pugh Score A5,A6,B7; 9. Liver function: ALT is less than 1.5 times of the upper limit of normal; ALT is less than 0.5 times of the upper limit of normal, AST can be less than 6 times of the upper limit of normal, excluding the elevation of AST caused by heart infarction; ALT is 0.5 to 1.5 times of the upper limit of normal, AST is less than 1.5 times of the upper limit of normal; 10. ECG examination showed no obvious abnormality, no obvious cardiac dysfunction; 11. Renal function: CRE and BUN were within 1.5 times of the upper limit of normal value; 12. Blood routine: HB ≥ 80g / L, ANC ≥ 1.0 × 109 / L, PLT ≥ 40 × 109 / L; 13. Coagulation function: no bleeding tendency; 14. Informed and voluntarily participated in the study and signed informed consent. Exclusion Criteria: 1. Currently in the process of other clinical trials within recently four weeks; 2. Previous abdominal radiotherapy and liver transplantation; 3. Patients with severe chronic diseases of heart, kidney, liver and other important organs; 4. Pregnant or lactating women; 5. Suspected or indeed drug abusers, drug abusers and alcoholics; 6. Allergic to lenvatinib or other treatments. 7. Severe mental or nervous system disorders affecting informed consent and / or expression or observation of adverse reaction